Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,717 | 370 | 99.7% |
| Education | $18.89 | 2 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $1,040 | 92 | $0 (2024) |
| Amgen Inc. | $928.67 | 47 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $493.45 | 29 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $468.48 | 31 | $0 (2024) |
| ABBVIE INC. | $345.21 | 20 | $0 (2024) |
| Lilly USA, LLC | $331.73 | 22 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $279.28 | 20 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $205.62 | 11 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $199.07 | 12 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $165.54 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $820.82 | 44 | Amgen Inc. ($279.45) |
| 2023 | $639.61 | 38 | Novo Nordisk Inc ($128.17) |
| 2022 | $696.08 | 43 | ABBVIE INC. ($215.70) |
| 2021 | $444.40 | 25 | AbbVie Inc. ($111.41) |
| 2020 | $267.32 | 18 | Novo Nordisk Inc ($52.78) |
| 2019 | $948.47 | 59 | Amgen Inc. ($215.47) |
| 2018 | $904.04 | 64 | SANOFI-AVENTIS U.S. LLC ($187.19) |
| 2017 | $1,016 | 81 | Novo Nordisk Inc ($210.01) |
All Payment Transactions
372 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.49 | General |
| Category: Gastroenterology | ||||||
| 12/02/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $15.70 | General |
| Category: Inflammation | ||||||
| 11/07/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $19.95 | General |
| Category: Cardio-renal | ||||||
| 11/06/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.42 | General |
| Category: Gastroenterology | ||||||
| 11/05/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $12.60 | General |
| Category: Bone Health | ||||||
| 10/29/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $18.33 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/22/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $13.97 | General |
| Category: Inflammation | ||||||
| 10/16/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $14.72 | General |
| Category: Diabetes | ||||||
| 09/17/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $10.95 | General |
| Category: Inflammation | ||||||
| 09/09/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $20.85 | General |
| Category: Biological | ||||||
| 08/22/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $18.92 | General |
| 08/20/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $14.73 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 08/08/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $12.06 | General |
| Category: Bone Health | ||||||
| 07/25/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $20.66 | General |
| Category: Inflammation | ||||||
| 07/11/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $24.13 | General |
| Category: Diabetes | ||||||
| 06/25/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $11.67 | General |
| Category: Bone Health | ||||||
| 06/18/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $14.77 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/13/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $18.89 | General |
| Category: Diabetes | ||||||
| 05/28/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $19.91 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/23/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $18.15 | General |
| Category: DIABETES | ||||||
| 05/22/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $110.53 | General |
| Category: Cardiology | ||||||
| 05/21/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $16.07 | General |
| Category: Diabetes | ||||||
| 05/02/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $16.72 | General |
| Category: PAIN | ||||||
| 04/29/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $18.02 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 04/25/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $20.38 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 706 | 1,511 | $148,380 | $86,227 |
| 2022 | 19 | 1,154 | 2,339 | $225,010 | $135,768 |
| 2021 | 17 | 1,087 | 2,635 | $250,320 | $150,434 |
| 2020 | 19 | 1,212 | 2,811 | $265,300 | $135,131 |
All Medicare Procedures & Services
71 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 221 | 846 | $118,440 | $72,151 | 60.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 43 | 57 | $5,415 | $2,828 | 52.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 20 | 20 | $3,100 | $2,492 | 80.4% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 104 | 104 | $2,600 | $1,845 | 71.0% |
| 87428 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza | Office | 2023 | 21 | 28 | $2,100 | $1,641 | 78.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 26 | 26 | $3,640 | $1,515 | 41.6% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 31 | 31 | $930.00 | $911.40 | 98.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 54 | 86 | $2,580 | $836.22 | 32.4% |
| 90686 | Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | Office | 2023 | 34 | 34 | $1,190 | $743.79 | 62.5% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 14 | 15 | $975.00 | $561.82 | 57.6% |
| 87880 | Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | Office | 2023 | 20 | 27 | $810.00 | $421.20 | 52.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 12 | 12 | $420.00 | $121.66 | 29.0% |
| 81003 | Automated urinalysis test | Office | 2023 | 31 | 54 | $810.00 | $118.80 | 14.7% |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | Office | 2023 | 16 | 54 | $1,080 | $20.04 | 1.9% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 28 | 39 | $1,170 | $14.37 | 1.2% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 31 | 78 | $3,120 | $6.51 | 0.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 272 | 1,076 | $150,570 | $95,145 | 63.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 119 | 119 | $18,445 | $15,073 | 81.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 138 | 261 | $24,795 | $11,764 | 47.4% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2022 | 14 | 15 | $3,750 | $2,962 | 79.0% |
| G0444 | Annual depression screening, 15 minutes | Office | 2022 | 161 | 161 | $4,025 | $2,860 | 71.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 32 | 32 | $4,480 | $2,083 | 46.5% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 44 | 45 | $1,350 | $1,277 | 94.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 59 | 122 | $3,660 | $1,262 | 34.5% |
| 90686 | Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | Office | 2022 | 44 | 46 | $1,610 | $969.58 | 60.2% |
About Dr. Hector Amaya Chinchilla, M.D
Dr. Hector Amaya Chinchilla, M.D is a Internal Medicine healthcare provider based in Weslaco, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/29/2008. The National Provider Identifier (NPI) number assigned to this provider is 1366690588.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Hector Amaya Chinchilla, M.D has received a total of $5,736 in payments from pharmaceutical and medical device companies, with $820.82 received in 2024. These payments were reported across 372 transactions from 32 companies. The most common payment nature is "Food and Beverage" ($5,717).
As a Medicare-enrolled provider, Amaya Chinchilla has provided services to 4,159 Medicare beneficiaries, totaling 9,296 services with total Medicare billing of $507,560. Data is available for 4 years (2020–2023), covering 71 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Location Weslaco, TX
- Active Since 08/29/2008
- Last Updated 04/22/2010
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1366690588
Products in Payments
- Ozempic (Drug) $398.22
- FARXIGA (Drug) $362.81
- XIFAXAN (Drug) $261.71
- Repatha (Biological) $258.11
- Victoza (Drug) $248.48
- Otezla (Drug) $236.09
- Aimovig (Biological) $235.61
- TOUJEO (Drug) $192.66
- JARDIANCE (Drug) $192.47
- VRAYLAR (Drug) $187.53
- ENTRESTO (Drug) $181.88
- SOLIQUA (Drug) $180.78
- XARELTO (Drug) $173.61
- MOUNJARO (Drug) $163.90
- Lucemyra/Lofexidine (Drug) $144.47
- Rybelsus (Drug) $136.55
- EVENITY (Biological) $126.87
- NUZYRA (Drug) $126.55
- UBRELVY (Drug) $104.26
- Kerendia (Drug) $97.85
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Weslaco
Dionisio Calvo
Internal Medicine — Payments: $4,184
Dr. Claudia Pierson, M.d, M.D
Internal Medicine — Payments: $3,969
Pedro Penalo, Md, MD
Internal Medicine — Payments: $3,559
Dr. Robert Sepulveda, M.d, M.D
Internal Medicine — Payments: $2,673
Jesus Rodriguez Hernandez, M.d, M.D
Internal Medicine — Payments: $2,593
Dr. Amrit Sraow, M.d, M.D
Internal Medicine — Payments: $1,916